

# Misdiagnosis is an important factor for diagnostic delay in McArdle disease

Renata Siciliani Scalco<sup>a,b,\*</sup>, Jasper M. Morrow<sup>a</sup>, Suzanne Booth<sup>a</sup>, Sherryl Chatfield<sup>a</sup>,  
Richard Godfrey<sup>a,c</sup>, Ros Quinlivan<sup>a,d</sup>

<sup>a</sup> MRC Centre for Neuromuscular Diseases and Department of Molecular Neuroscience, University College London Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK

<sup>b</sup> CAPES Foundation, Ministry of Education of Brazil, Brasilia, DF, Brazil

<sup>c</sup> Centre for Human Performance, Exercise and Rehabilitation, Brunel University London, London UB8 3PH, UK

<sup>d</sup> Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London WC1N 3JH, UK

Received 17 January 2017; received in revised form 29 March 2017; accepted 28 April 2017

## Abstract

Diagnosis of McArdle disease is frequently delayed by many years following the first presentation of symptoms to a health professional. The aim of this study was to investigate the importance of misdiagnosis in delaying diagnosis of McArdle disease. The frequency of misdiagnosis, duration of diagnostic delay, categories of misdiagnoses and inappropriate medical interventions were assessed in 50 genetically confirmed patients. The results demonstrated a high frequency of misdiagnosis (90%,  $n = 45/50$ ) most commonly during childhood years (67%;  $n = 30/45$ ) compared with teenage years and adulthood (teenage:  $n = 7/45$ ; adult  $n = 5/45$ ; not known  $n = 3/45$ ). The correct diagnosis of McArdle disease was rarely made before adulthood (median age of diagnosis 33 years). Thirty-one patients (62%) reported having received more than one misdiagnosis; the most common were “growing pains” (40%,  $n = 20$ ) and “laziness/being unfit” (46%,  $n = 23$ ). A psychiatric/psychological misdiagnosis was significantly more common in females than males (females 6/20; males 1/30;  $p < 0.01$ ). Of the 45 patients who were misdiagnosed, 21 (47%) received incorrect management. This study shows that most patients with McArdle disease received an incorrect explanation of their symptoms providing evidence that misdiagnosis plays an important part in delaying implementation of appropriate medical advice and management to this group of patients.

© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:** Glycogen storage disease type V; McArdle disease; Growing pains; Exercise intolerance; Rhabdomyolysis; Myoglobinuria

## 1. Introduction

McArdle disease (GSDV) is an autosomal recessive disorder characterised by the absence of muscle glycogen phosphorylase. The enzyme deficit results in impaired muscle metabolism with symptoms such as exercise intolerance and muscle pain beginning in childhood. Muscle pain occurs within a few minutes of starting physical activity and can lead to muscle contracture and rhabdomyolysis (RM) if that activity persists or is more vigorous. Muscle contracture and RM in McArdle disease do not just follow exercise and can also be triggered by sustained isometric muscle contraction in everyday activities or ‘unusual’

circumstances [1,2]. RM may result in potential life-threatening complications requiring urgent hospital admission such as compartment syndrome and acute kidney failure (Table 1).

Early diagnosis, ideally when the individual is still a child, is important to facilitate learning the life skills required to manage the condition and prevent RM [3]. Timely diagnosis facilitates appropriate screening, management and prevention of known comorbidities associated with the condition such as sedentariness and obesity [4]. Currently, a correct diagnosis frequently occurs years after first presentation of symptoms [5–8]. This could, in part, be due to its rarity, as doctors might not be familiar with the clinical hallmarks of the condition such as the *second wind* phenomenon, which occurs after about 8–10 minutes of aerobic activity when the symptoms of exercise intolerance (tachycardia, myalgia and fatigue) disappear and the patient can exercise more freely.

\* Corresponding author. MRC Centre for Neuromuscular Diseases, Queen Square, London WC1N 3BG, UK. Fax: +0203 448 4725.

E-mail address: [r.scalco@ucl.ac.uk](mailto:r.scalco@ucl.ac.uk) (R.S. Scalco).

Table 1  
McArdle disease diagnostic features.

McArdle disease features	Medical history/Physical exam
Exertion intolerance	Episodes of muscle pain and tachycardia at the beginning of any physical activity and during strenuous activity, isometric muscle contraction and/or resistance training. All skeletal muscles are involved. In children symptoms reported by parents include: <ul style="list-style-type: none"> <li>• Infancy: difficulty crawling more than a few yards</li> <li>• Toddlers: wanting to be carried/or put in a push-chair all of the time, complaining of pain when walking</li> <li>• Children: <ul style="list-style-type: none"> <li>○ unable to run (maximum running distance 100 m)</li> <li>○ unable to keep up with peers</li> <li>○ collapse/vomiting during sporting activities</li> </ul> </li> </ul>
Muscle contracture	Severe rigidity with associated pain (patients might report it as “muscle seizes up”, “severe cramp”). Muscle contracture may affect any skeletal muscle, for example the forearm, with activities such as opening cans, picking up heavy pots, carrying shopping.
<i>Second wind</i>	During aerobic activity symptoms improve after 8–10 minutes. The <i>second wind</i> can be identified with functional exercise testing with cardiac monitoring such as the 12 minute walk test or cycle ergometry [7,9–11].
Episodes of rhabdomyolysis/myoglobinuria	Severe muscle contracture followed by muscle swelling and pain; flu-like symptoms Discolouration of urine described as: tea, red wine or coca cola With severe episodes there may be collapse and acute renal failure CK is markedly raised (40,000–250,000 IU/L)
Additional investigation	Baseline serum CK is usually raised (10–15× normal) Serum urate is frequently raised Non-ischemic forearm exercise test shows no significant rise in lactate DNA analysis: Initial screen for common mutations in Northern Europeans (p.Arg50X and p.Gly205Ser) Next tier full <i>PYGM</i> sequencing Muscle biopsy rarely required: vacuolar myopathy, sub-sarcolemmal glycogen deposition and absent muscle glycogen phosphorylase activity

CK, creatine kinase.

To investigate the consequences of disease misdiagnosis in McArdle disease patients, a service evaluation was performed to assess the frequency of misdiagnosis, the duration of diagnostic delay, the categories of misdiagnoses and inappropriate medical interventions.

## 2. Materials and methods

Clinical information from 50 consecutive patients with genetically confirmed GSDV (median age: 48.14; range: 16–73; 30 male, 20 female) was reviewed as part of service evaluation of a ‘Nationally Commissioned Highly Specialized McArdle’s Disease Service’ based in London. The study was registered and approved by the Hospital’s internal review board/audit committee. As this was a service evaluation, informed consent was not required. Detailed data on diagnosis and misdiagnosis are routinely collected as part of patients’ assessment at the UK specialised service. Further information is also available on NHS referral documentation and GP records/referral letter. Data related to onset of symptoms, year of diagnosis and related misdiagnoses, self-perception of GSDV symptoms and incorrect treatment prescription were collected via medical notes review and patients’ personal experience reports using a standardised pre-agreed data extraction form. All data were anonymised, and individual details and precise description of various misdiagnoses and incorrect treatment that could potentially identify an individual were omitted. In patients where more than one misdiagnosis had occurred, we reported data based on the age at the first misdiagnosis. Non-parametric data are

summarised as median (range). Categorical data are summarised as percentages. Gender differences were assessed using Mann–Whitney U tests for continuous variables and chi-squared tests for proportions.

## 3. Results

The frequency of misdiagnosis in patients with GSDV was 90% (n = 45/50). First misdiagnosis most frequently occurred during childhood years (67%; n = 30/45), and less frequently during teenage years or adulthood (teenage: n = 7/45; adult n = 5/45; not known n = 3/45). However, ongoing or additional misdiagnoses were common through adult years with the median age of correct diagnosis being 33 years (range 6–70). The median delay in correct diagnosis of GSDV was 29 years (range 0–68). The median time from symptom onset to receiving the first misdiagnosis was 3 years (range 0–67). The median time from the misdiagnosis to correct diagnosis was 23 years (range 1–62). There were no significant gender differences in any of these parameters. The diagnostic delay from the first symptoms to the correct diagnosis appeared to decrease over the decades (Fig. 1A). This decrease was associated with an increase in GSDV diagnostic rates with time (Fig. 1B).

Thirty-one patients (62%) reported having received more than one misdiagnosis, with “growing pains” (40%, n = 20) and “laziness/being unfit” (46%, n = 23) representing the most common misdiagnoses (Fig. 2). A psychiatric/psychological misdiagnosis was significantly more common in females than




Fig. 1. A: Scatter plot of year of first symptoms versus delay from first symptoms to diagnosis. Diagnostic delay reduces as year of first symptoms increases; however patients with recent onset of symptoms who are yet to be diagnosed will not have been captured. There is a dramatic increase in number of diagnoses made after genetic testing became available in the late 1990s, with 9 diagnoses made from 1990 to 2000, and 19 from 2000 to 2010. B: Scatter plot of year of first symptoms versus year of diagnosis.

males (females 6/20; males 1/30;  $p < 0.01$ ), but there weren't significant gender differences in the other categories. Notably six patients self-diagnosed their GSDV following library or internet searches. Of the 45 patients who were misdiagnosed, 21 (47%) received incorrect management, with 13 (29%) receiving inappropriate exercise training advice (e.g. being advised to ignore symptoms of pain during exercise, or alternatively, being advised to avoid exercise altogether) and 12 (27%) receiving another medical intervention including antibiotic prescription, sternum surgery, tonsillectomy and invasive procedures such




Fig. 2. The total number of times misdiagnoses were reported by 45 genetically confirmed McArdle disease patients according to the categories of misdiagnosis and gender (female: dark grey, male: diagonal stripes). Several patients reported more than one misdiagnosis, and so the total frequency exceeded the number of assessed patients. RHEUM, rheumatic disorders; PSYCH, psychological conditions; NMD, neuromuscular diseases.

as cystoscopy [2]. Inappropriate exercise prescription that was too intense following a misdiagnosis of “laziness/being unfit” resulted in muscle damage and RM in a few patients. A few patients reported that, prior to diagnosis, bullying at school was a problem especially during physical education lessons, causing further emotional stress.

#### 4. Discussion

A correct diagnosis is rarely identified before adulthood in people with GSDV with a median age of diagnosis of 33 years, despite symptoms starting at a median of 3 years of age. This study shows that most patients with GSDV will have sought medical assessment during childhood but received an incorrect explanation of their symptoms, providing evidence that misdiagnosis plays an important part in delaying correct diagnosis and implementation of appropriate medical advice. The median diagnostic delay in patients with GSDV was 29 years, which is in accord with age of diagnosis reported worldwide, usually between the 2nd to 5th decades [5–8]. Prevention of life-threatening complications such as acute RM, through timely diagnosis and appropriate management of the condition, has obvious health benefits, but also wider benefits to the healthcare economy by reducing the need for critical care admissions and avoiding costly treatment plans that may be associated with diagnostic errors.

In the UK, the time from first symptoms to diagnosis has decreased in recent decades. This could be explained by increased awareness of the condition and the development of a national service funded by the NHS. GSDV was first described in 1951 [12]. Originally, diagnosis was made by forearm exercise test showing no rise in lactate and a muscle biopsy showing absent staining for muscle glycogen phosphorylase. Genetic diagnosis (*PYGM*) became available from the late 1990s. In the UK and northern Europe up to 85% of the

GSDV population can be diagnosed by screening the two most common mutations (p.Arg50X and p.Gly205Ser), which is cheap and efficient costing only £120 [8]. More recently, next generation sequencing panels for glycogen storage diseases and disorders associated with RM have become available, facilitating the genetic investigation of people presenting with exercise intolerance and/or recurrent RM [13]. In addition, the nationally commissioned highly specialised multi-disciplinary service for diagnosis and management of people with GSDV, first established in 2012, has had a positive impact on dissemination and training health care professionals. Establishing this highly specialised service has also resulted in faster diagnosis and improved patient care, with a documented reduction in McArdle disease-related complications [4]. Public awareness of the condition has also improved as a result of the work of the Association for Glycogen Storage Disease–UK (AGSD-UK) created in 1986 [14]. AGSD-UK has provided support to patients in clinic, organised walking courses and produced videos and publications [15].

Thus, improvements in the genetic diagnostic techniques, the creation of the highly specialised service and the AGSD-UK have positively contributed to the increase in early diagnosis. Measures to improve the diagnosis of GSDV such as dissemination and training were also implemented in Europe by the Euromac registry and network funded by the Health Programme of the European Union [10,16,17].

Even though data presented here confirmed that people are being diagnosed with GSDV earlier in life, which seems to correlate with a decrease in the diagnostic delay, we are unable to confirm how many patients are still undiagnosed. Recall bias regarding personal experiences from patients' past medical history is also a limitation of this study. Data acquired by the Euromac registry will help to confirm the accuracy of the collected data and help to determine if the decreasing trend is consistent.

## 5. Conclusions

In summary, misdiagnosis plays an important role in delaying GSDV diagnosis. Addressing misdiagnosis may be an issue of education since GSDV is a rare disorder. Efforts made to increase the awareness of the condition in the UK as summarised in this report suggest a positive impact in reducing the diagnostic delay.

## Acknowledgements

The authors would like to thank Mr Andrew Wakelin for his great and inspiring work. The authors would also like to thank

AGSD-UK, CAPES Foundation, Muscular Dystrophy Campaign and the Euromac Registry for their support.

## References

- [1] Brady S, Godfrey R, Scalco RS, Quinlivan RM. Emotionally-intense situations can result in rhabdomyolysis in McArdle disease. *BMJ Case Rep* 2014;2014.
- [2] Scalco RS, Chatfield S, Junejo MH, Booth S, Pattni J, Godfrey R, et al. McArdle disease misdiagnosed as meningitis. *Am J Case Rep* 2016;17:905–8.
- [3] Nogales-Gadea G, Santalla A, Ballester-Lopez A, Arenas J, Martin MA, Godfrey R, et al. Exercise and preexercise nutrition as treatment for McArdle disease. *Med Sci Sports Exerc* 2016;48(4):673–9.
- [4] Scalco RS, Blooth S, Ellerton C, Godfrey R, Kahraman A, Wigley R, et al. P111 Effect of a multi-disciplinary approach to diagnosis and management for non-lysosomal skeletal muscle glycogen storage disorders. *Neuromuscul Disord* 2016;26(Suppl. 1):S38.
- [5] Lucia A, Ruiz JR, Santalla A, Nogales-Gadea G, Rubio JC, Garcia-Consuegra I, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. *J Neurol Neurosurg Psychiatry* 2012;83(3):322–8.
- [6] Santalla A, Nogales-Gadea G, Blázquez Encinar A, Vieitez I, González-Quintana A, Serrano-Lorenzo P, et al. Genotypic and phenotypic features of all Spanish patients with McArdle disease: A 2016 update. *BMC Genomics* 2017;2017:in press.
- [7] Quinlivan R, Vissing J. 144th ENMC international workshop: outcome measures in McArdle disease, 29 September–1 November 2006, Naarden, The Netherlands. *Neuromuscul Disord* 2007;17(6):494–8.
- [8] Quinlivan R, Buckley J, James M, Twist A, Ball S, Duno M, et al. McArdle disease: a clinical review. *J Neurol Neurosurg Psychiatry* 2010;81(11):1182–8.
- [9] Scalco RS, Chatfield S, Godfrey R, Pattni J, Ellerton C, Beggs A, et al. From exercise intolerance to functional improvement: the second wind phenomenon in the identification of McArdle disease. *Arq Neuro-Psiquiatr* 2014;72(7):538–41.
- [10] Quinlivan R, Lucia A, Scalco RS, Santana A, Parini J, Godfrey R, et al. Report on the EUROMAC McArdle exercise testing workshop, Madrid, Spain, 11–12 July 2014. *Neuromuscul Disord* 2015;25(9):739–45.
- [11] Buckley JP, Quinlivan RM, Sim J, Eston RG, Short DS. Heart rate and perceived muscle pain responses to a functional walking test in McArdle disease. *J Sports Sci* 2014;32(16):1561–9.
- [12] McArdle B. Myopathy due to a defect in muscle glycogen breakdown. *Clin Sci* 1951;10(1):13–35.
- [13] Scalco RS, Gardiner AR, Pitceathly RD, Zanoteli E, Becker J, Holton JL, et al. Rhabdomyolysis: a genetic perspective. *Orphanet J Rare Dis* 2015; 10:51.
- [14] Wakelin A. Association for Glycogen Storage Disease (UK); 1986. Available from: <http://www.agsd.org.uk>.
- [15] Wakelin A. 101 Tips for a good life with McArdle disease. In: Wakelin A, editor. Association for Glycogen Storage Diseases: AGSD-UK; 2013.
- [16] EUROMAC. EUROMAC registry introduction; 2013. Available from: <http://www.youtube.com/watch?v=NXvmRGLcIy8>.
- [17] EUROMAC. EUROMAC registry of patients with McArdle Disease and other rare glycogenolytic disorders with exercise intolerance; 2013. Available from: <http://www.euromacregistry.eu>.